Lecanemab and donanemab, monoclonal antibodies for Alzheimer’s, are on the list of drugs in late-stage development that Clarivate analysts will have annual sales of a $1 billion or more in the next five years.
In a new report, analysts at Clarivate, a London-based intelligence and research firm, identified seven experimental treatments in late-stage development that they expect to deliver annual sales of more $1 billion within five years.
They include treatments for common conditions such as Alzheimer’s disease and asthma to those for very rare diseases such as transthyretin amyloidosis, which is characterized by a build-up of deposits of amyloid, a protein, in various organs.Transthyretin amyloidosis is less common among Americans of European descent, where it is estimated to affect one in 100,000 people, but cardiac form affects between 3% and 3.9% of African Americans.
Here are the seven treatments that are likely to achieve blockbuster status in the next five years according to Clarivate:
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More